BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Othera Pharmaceuticals Reports Preserved Visual Function in Clinical Trial of OT-551 Eye Drop Treatment for Advanced Dry AMD


3/23/2010 12:45:58 PM

WEST CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Othera Pharmaceuticals, Inc., a specialty pharmaceutical company focused on treatments for ophthalmic diseases, today announced positive visual function results from a Phase I/II trial of OT-551 conducted at the National Eye Institute (NEI) of the National Institutes of Health (NIH) in patients with bilateral geographic atrophy, an advanced form of dry age-related macular degeneration (dry AMD). Results of this study will be the subject of a poster presentation as part of the “Late Breaking Posters” section at the Association for Research in Vision and Ophthalmology (ARVO) 2010 Annual Meeting, to be held May 2 – 6 in Fort Lauderdale, Florida. A second poster will also present incomplete results from the OMEGA Phase II trial of OT-551, which enrolled a different patient population and employed a different dosing regimen than the NEI study.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES